— Know what they know.
Not Investment Advice

KIN NASDAQ

Kindred Biosciences, Inc.
1W: +0.2% 1M: +1.9% 3M: +91.5% 1Y: +134.2% 3Y: -37.3% 5Y: +108.3%
$9.25
Last traded 2021-08-27 — delisted
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

Cash Flow Trends

Operating Cash Flow
-$10M +82.5% ▲
Capital Expenditures
$4M +56.8% ▲
5Y CAGR: +37.9%
Free Cash Flow
-$13M +79.2% ▲
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
-$4M +89.2% ▲

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2016FY2017FY2018FY2019FY2020
— Operating Activities —
Net Income-$22M-$31M-$50M-$61M-$22M
Depreciation & Amort.$155K$475K$805K$3M$5M
Stock-Based Comp.$4M$5M$6M$7M$8M
Change in Working Capital-$341K$3M-$2M-$5M-$5M
Other Non-Cash Items$277K$189K-$145K-$156K$4M
Operating Cash Flow-$19M-$22M-$45M-$56M-$10M
— Investing Activities —
Capital Expenditures-$952K-$6M-$14M-$8M-$4M
Acquisitions (Net)$0$0$0$0$0
Investment Purchases-$72M-$70M-$25M-$125M-$76M
Investment Sales$78M$73M$55M$86M$85M
Other Investing$0$0$248K$5K$82K
Investing Cash Flow$5M-$3M$17M-$48M$6M
— Financing Activities —
Net Debt Issuance$0$0$0$0$0
Stock Repurchased$0$0-$247K$0$0
Dividends Paid$0$0$0$0$0
Other Financing$162K$53M$50M$64M-$282K
Financing Cash Flow$162K$53M$50M$64M-$282K
Net Change in Cash-$13M$28M$21M-$40M-$4M
Cash End of Period$7M$35M$56M$16M$12M
Free Cash Flow-$20M-$28M-$59M-$65M-$13M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms